(Total Views: 749)
Posted On: 04/07/2020 11:38:07 AM
Post# of 149235
NP at his best:
"We are humbled by the outpouring of inquiries and requests for access to leronlimab and are working around the clock with our many partners to facilitate access to a potential therapeutic benefit for COVID-19 patients."
The COVID-19 story also highlights the huge potential for the leronlimab pneumonia indication with the market of well over 3 million cases annually and mortality rate for severe cases of about 20% (common for people over 65). Pneumonia is also the leading cause of death for children under 5.
"We are humbled by the outpouring of inquiries and requests for access to leronlimab and are working around the clock with our many partners to facilitate access to a potential therapeutic benefit for COVID-19 patients."
The COVID-19 story also highlights the huge potential for the leronlimab pneumonia indication with the market of well over 3 million cases annually and mortality rate for severe cases of about 20% (common for people over 65). Pneumonia is also the leading cause of death for children under 5.
(8)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
